

MARV virus-like particles (MARV VLP)

Catalog #: 0566-001

Lot #: 1511005

Description: Virus-like Particles (VLP's) expressing recombinant Marburg (Musoke) virus (MMARV) glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40). These VLP's are produced in Sf9 insect cells through infection with a recombinant baculovirus.


Storage: 2-3 weeks at -20°C, -80°C long term

Size: 1 mg of protein supplied in PBS (supplemented with glycerol, arginine and glutamic acid) at a concentration of **3.725 mg/mL**.

Relevance: Since these VLP's mimic MARV (Musoke) virus but do not contain genetic material, thus are not infectious and make an ideal candidate as a vaccine and also as a tool to enhance filovirus research.

Related Products: IBT provides a wide array of anti-filovirus specific antibodies and other infectious disease reagents. Please see our website, www.ibtbioservices.com for more details.

Western Blot Detection



Western Blot was used to confirm the presence of MMARV-specific GP, NP and VP40 in the VLP. VLP sample was heat-denatured under reducing condition and loaded at 1 µg/lane.

(A) GP was detected as a broadly-diffused band 60-160 kDa using 0.1 µg/mL of anti-MARV GP mouse mAb (5C1) (cat# 0203-023).

(B) NP was detected as a prominent band at ~90 kDa and other NP-containing fragments, using 0.1 µg/mL of anti-MARV NP rabbit Pab (cat# 0303-012).

(C) VP40 was detected as a prominent band at ~35 kDa and other VP40-containing fragments, using 0.1 µg/mL of anti-MARV VP40 rabbit Pab (cat# 0303-001).

Intended for research use only, not for human, therapeutic, or diagnostic applications.

The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, Inc.

Copyright 2015. Integrated BioTherapeutics, Inc. All rights reserved.